Methods comprising desmopressin

Abstract

The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.

1 . A method for reducing nocturnal voids in a patient in need thereof comprising:
 administering to the patient prior to bedtime an orodispersible dose of desmopressin ranging from 25 μg to 100 μg, wherein the dose is measured as the free base of desmopressin and the dose taken over a minimum treatment period reduces the patient's nocturnal voids compared to the patient's nocturnal voids before administration of the dose.   
     
     
         2 . The method according to  claim 1 , wherein the dose is taken from 0.8 to 3 hours prior to the patient's bedtime. 
     
     
         3 . The method according to  claim 1 , wherein the dose is taken once daily. 
     
     
         4 . The method according to  claim 1 , wherein the dose of desmopressin free base is supplied in the form of the acetate salt of desmopressin. 
     
     
         5 . The method according to  claim 1 , wherein the orodispersible dose of desmopressin is a dosage form comprising desmopressin acetate, gelatin, mannitol, and citric acid. 
     
     
         6 . The method according to  claim 1 , wherein the patient in need thereof has nocturia or nocturnal polyuria. 
     
     
         7 . The method according to  claim 1 , wherein the reduction in nocturnal voids ranges from about one nocturnal void to about two nocturnal voids compared to the patient's nocturnal voids before administration of the dose. 
     
     
         8 . The method according to  claim 1 , wherein the minimum treatment period is greater than 28 days. 
     
     
         9 . The method according to  claim 8 , wherein the minimum treatment period is at least one year. 
     
     
         10 . The method according to  claim 1 , wherein the patient is male. 
     
     
         11 . The method according to  claim 10 , wherein the reduction in nocturnal voids is at least about one nocturnal void compared to the patient's nocturnal voids before administration of the dose. 
     
     
         12 . The method according to  claim 1 , wherein the patient is female. 
     
     
         13 . The method according to  claim 12 , wherein the reduction in nocturnal voids is greater than one nocturnal void compared to the patient's nocturnal voids before administration of the dose. 
     
     
         14 . A method for improving a reduction in nocturnal voids in a patient in need thereof comprising:
 administering to the patient prior to bedtime an orodispersible dose of desmopressin ranging from 25 μg to 100 μg, wherein the dose is measured as the free base of desmopressin and the dose taken over a minimum treatment period reduces the patient's nocturnal voids compared to before administration and improves the reduction in nocturnal voids over the duration of the minimum treatment period.   
     
     
         15 . The method according to  claim 14 , wherein the dose is taken from 0.8 to 3 hours prior to the patient's bedtime. 
     
     
         16 . The method according to  claim 14 , wherein the dose is taken once daily. 
     
     
         17 . The method according to  claim 14 , wherein the dose of desmopressin free base is supplied in the form of the acetate salt of desmopressin. 
     
     
         18 . The method according to  claim 14 , wherein the orodispersible dose of desmopressin is a dosage form comprising desmopressin acetate, gelatin, mannitol, and citric acid. 
     
     
         19 . The method according to  claim 14 , wherein the patient in need thereof has nocturia or nocturnal polyuria. 
     
     
         20 . The method according to  claim 14 , wherein the reduction in nocturnal voids ranges from about one nocturnal void to about two nocturnal voids compared to the patient's nocturnal voids before administration of the dose. 
     
     
         21 . The method according to  claim 14 , wherein the minimum treatment period is greater than 28 days. 
     
     
         22 . The method according to  claim 21 , wherein the minimum treatment period is at least one year. 
     
     
         23 . The method according to  claim 14 , wherein the patient is male. 
     
     
         24 . The method according to  claim 23 , wherein the reduction in nocturnal voids is at least about one nocturnal void compared to the patient's nocturnal voids before administration of the dose. 
     
     
         25 . The method according to  claim 14 , wherein the patient is female. 
     
     
         26 . The method according to  claim 25 , wherein the reduction in nocturnal voids is greater than one nocturnal void compared to the patient's nocturnal voids before administration of the dose. 
     
     
         27 . A method for maintaining a reduction in nocturnal voids in a patient in need thereof comprising:
 administering to the patient prior to bedtime an orodispersible dose of desmopressin of ranging from 25 μg to 100 μg, wherein the dose is measured as the free base of desmopressin and the dose is taken over a minimum treatment period reduces the patient's nocturnal voids compared to the patient's nocturnal voids before administration of the dose.